Edwards CEO sells 523 EW shares at $87.92

Edwards Lifesciences Corp CEO Bernard J. Zovighian reported an open-market sale of 523 shares of Common Stock at $87.92 per share.

Rhea-AI Filing Summary

Edwards Lifesciences Corp CEO Bernard J. Zovighian reported an open-market sale of 523 shares of Common Stock at $87.92 per share. The shares were held indirectly through a trust, which held 11,516.5511 shares after the transaction.

The filing also shows 3,733.5603 shares held indirectly through a 401(k) plan and 99,164.6499 shares held directly as of the same date. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating it was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 523 shares

Net Sell 3 txns

Insider Zovighian Bernard J

Role CEO

Sold 523 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Common Stock	523	$87.92	$46K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 11,516.5511 shares (Indirect, By Trust); Common Stock — 99,164.6499 shares (Direct); Common Stock — 3,733.5603 shares (Indirect, 401(k))

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

Key Figures

Shares sold: 523 shares Sale price: $87.92 per share Trust holdings after sale: 11,516.5511 shares +2 more

5 metrics

Shares sold 523 shares Open-market sale of Common Stock on June 17, 2026

Sale price $87.92 per share Price received for 523-share sale of Common Stock

Trust holdings after sale 11,516.5511 shares Indirect ownership by trust following sale

401(k) holdings 3,733.5603 shares Indirect Common Stock holdings via 401(k) as of transaction date

Direct holdings 99,164.6499 shares Directly owned Common Stock as of transaction date

Key Terms

Rule 10b5-1 trading plan, open-market sale, indirect, 401(k), +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect financial

""ownership_type": "indirect""

401(k) financial

""nature_of_ownership": "401(k)""

A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.

By Trust financial

""nature_of_ownership": "By Trust""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edwards Lifesciences (EW) report for CEO Bernard Zovighian?

Edwards Lifesciences reported that CEO Bernard J. Zovighian sold 523 shares of Common Stock in an open-market transaction at $87.92 per share. The shares were held indirectly through a trust, which retained 11,516.5511 shares after the sale.

Was the Edwards Lifesciences (EW) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The sale was executed under a Rule 10b5-1 trading plan adopted on December 12, 2025. Such plans pre-schedule trades, meaning the timing of this 523-share sale was set in advance rather than decided opportunistically.

How many Edwards Lifesciences (EW) shares does the CEO hold after the reported sale?

After the reported transactions, the CEO’s trust held 11,516.5511 shares, his 401(k) held 3,733.5603 shares, and he held 99,164.6499 shares directly. These figures come from separate line items for indirect and direct ownership in the filing.

What price did the Edwards Lifesciences (EW) CEO receive for the shares sold?

The CEO’s trust sold 523 shares of Edwards Lifesciences Common Stock at $87.92 per share. This per-share price reflects the average sale price disclosed for the open-market or private transaction reported in the Form 4 filing.

How many total shares were involved in the Edwards Lifesciences (EW) CEO’s sale?

The filing reports a single open-market sale of 523 shares of Common Stock. Additional line items show updated holdings in a trust, a 401(k), and direct ownership, but only the 523 shares were identified as sold in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 08:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zovighian Bernard J

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S(1)		523	D	$87.92	11,516.5511	I	By Trust
Common Stock								99,164.6499	D
Common Stock								3,733.5603	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)